Last reviewed · How we verify

NCT07240077: BLESS

Beta-lactam Plus Levofloxacin to Enhance Therapy in Streptococcal Septicemia

Not yet recruiting Phase 4 Last updated 20 November 2025
What this trial tests

Phase 4 trial testing Beta-lactam monotherapy in Bacteremia in 165 participants. Not yet recruiting.

Timeline
1 January 2026
Primary endpoint
31 December 2027
31 December 2028

Quick facts

Lead sponsorMahidol University
PhasePhase 4
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposetreatment
Enrollment165
Start date1 January 2026
Primary completion31 December 2027
Estimated completion31 December 2028
Sites4 locations across Thailand

Drugs / interventions tested

Conditions studied

Sponsor

Mahidol University

Who can join

18 and older, any sex, with Bacteremia or Streptococcus Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A double-blind randomized controlled trial comparing beta-lactam plus levofloxacin versus beta-lactam monotherapy for the treatment of Streptococcal bacteremia

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Bacteremia

Currently open trials in the same condition.

Other Mahidol University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07240077.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing